Last reviewed · How we verify
No postpartum antibiotics
This is not a drug but rather a clinical practice guideline or study protocol examining outcomes when postpartum antibiotic prophylaxis is omitted.
This is not a drug but rather a clinical practice guideline or study protocol examining outcomes when postpartum antibiotic prophylaxis is omitted. Used for Postpartum infection prevention strategy evaluation.
At a glance
| Generic name | No postpartum antibiotics |
|---|---|
| Sponsor | Washington University School of Medicine |
| Modality | Small molecule |
| Therapeutic area | Obstetrics/Gynecology |
| Phase | FDA-approved |
Mechanism of action
This appears to be a research initiative or quality improvement project from Washington University School of Medicine evaluating the safety and efficacy of withholding routine antibiotic prophylaxis in the postpartum period. It is not a pharmaceutical agent with a mechanistic action, but rather an evidence-based practice comparison or clinical trial design.
Approved indications
- Postpartum infection prevention strategy evaluation
Common side effects
Key clinical trials
- Maternal Probiotic Intervention to Improve Gut Health-Trial II-Pakistan (PHASE2)
- Azithromycin for Preventing Maternal and Neonatal Infections During Labor. (PHASE4)
- Surgical Site Infection After Episiotomy Repair Related to Routine Use of Antibiotic Prophylaxis in Low-Risk Population
- Lidocaine, Povidone Iodine, and Honey Application on Second-degree Perineal Tear Healing (PHASE4)
- Efficacy of Azithromycin in MSAF Cases to Improve Maternal and Neonatal Outcomes (PHASE4)
- EGF-loaded Chitosan to Facilitate Healing and Prevent Scar Formation of Cesarean Wound (NA)
- A Comparative Study Between Bakri Balloon and B Lynch Suture Used to Control Primary Postpartum Hemorrhage After Cesarean Section (NA)
- Treatment Utility of Postpartum Antibiotics in Chorioamnionitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- No postpartum antibiotics CI brief — competitive landscape report
- No postpartum antibiotics updates RSS · CI watch RSS
- Washington University School of Medicine portfolio CI